ABSTRACT
A combination drug therapy (Qsymia) for obesity consisting of phentermine and topiramate was approved by the U.S. Food and Drug Administration (FDA) in July 2012. This chapter reviews the basis for combining these two drugs, the efcacy and safety of the combination therapy as demonstrated in clinical trials, and its clinical applications.
